What is Edison Pharmaceuticals?
Headquartered in Lakeville, Massachusetts, Edison Pharmaceuticals operates as a specialized entity within the pharmaceutical industry. With a workforce of 20 to 49 employees and annual revenues ranging between 10M and 25M, the company maintains a focused operational footprint. Its core business model centers on the development of innovative therapeutic solutions, positioning it as a niche player capable of navigating the complex regulatory and clinical landscapes inherent to drug discovery and commercialization. The company's ability to sustain growth through multiple funding rounds highlights its resilience and the perceived value of its intellectual property portfolio.
How much funding has Edison Pharmaceuticals raised?
Edison Pharmaceuticals has raised a total of $87M across 7 funding rounds:
Series A
$2.8M
Series B
$4.3M
Series C
$2.8M
Series D
$3M
Series E
$4.1M
Series F
$20M
Private Equity
$50M
Series A (2005): $2.8M with participation from Paul Avery
Series B (2007): $4.3M, investors not publicly disclosed
Series C (2009): $2.8M, investors not publicly disclosed
Series D (2010): $3M, investors not publicly disclosed
Series E (2012): $4.1M, investors not publicly disclosed
Series F (2012): $20M with participation from Mitsui & Co.
Private Equity (2014): $50M led by Dainippon Sumitomo Pharma Co., Ltd
Key Investors in Edison Pharmaceuticals
Dainippon Sumitomo Pharma Co., Ltd
Sumitomo Dainippon Pharma Co Ltd is a major pharmaceutical enterprise based in Osaka, Japan, with a significant global workforce and extensive experience in drug development.
Mitsui & Co.
Mitsui & Co. is a global trading and investment firm that focuses on infrastructure, energy transition, and healthcare solutions to create long-term sustainable value.
Paul Avery
An individual investor who participated in the early-stage financing rounds of the company.
What's next for Edison Pharmaceuticals?
Looking ahead, the recent capital influx is expected to accelerate the company's research and development initiatives, potentially shortening the time-to-market for its lead candidates. As Edison Pharmaceuticals moves into its next phase of maturity, the focus will likely shift toward expanding its clinical trial capacity and strengthening its commercial infrastructure. The strategic alignment with global pharmaceutical leaders suggests a potential for future collaborative ventures or licensing agreements that could further enhance the company's market reach. Investors will be closely monitoring the firm's ability to convert this latest financing into tangible clinical milestones and sustainable revenue growth in the coming fiscal periods.
See full Edison Pharmaceuticals company page
